Do analysts rate DOCS or RMG?

Dr. Martens currently has a consensus target price of GBX 105, indicating a potential upside of 50.32%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Royal Mail. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Martens 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Royal Mail 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, VTY or DOCS?

Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vistry Group £3.61B 0.21 £245.05M £42.00 5.67 Dr. Martens £764.90M 0.87 £68.97M £2.40 29.11

Is VTY or DOCS more profitable?

Vistry Group has a net margin of 3.82% compared to Dr. Martens' net margin of 3.11%. Dr. Martens' return on equity of 6.89% beat Vistry Group's return on equity. Company Net Margins Return on Equity Return on Assets Vistry Group 3.82% 4.20% 3.43% Dr. Martens 3.11% 6.89% 8.12%

Does the media favor VTY or DOCS?

In the previous week, Vistry Group and Vistry Group both had 1 articles in the media. Dr. Martens' average media sentiment score of 1.38 beat Vistry Group's score of -0.28 indicating that Dr. Martens is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vistry Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Martens 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, GEN or DOCS?

Dr. Martens has higher revenue and earnings than Genuit Group. Genuit Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genuit Group £602.10M 1.10 £23.57M £17.80 14.79 Dr. Martens £764.90M 0.87 £68.97M £2.40 29.11

Is GEN or DOCS more profitable?

Genuit Group has a net margin of 7.51% compared to Dr. Martens' net margin of 3.11%. Genuit Group's return on equity of 6.89% beat Dr. Martens' return on equity. Company Net Margins Return on Equity Return on Assets Genuit Group 7.51% 6.89% 4.59% Dr. Martens 3.11% 6.89% 8.12%

Which has higher valuation and earnings, DOCS or WIX?

Dr. Martens has higher earnings, but lower revenue than Wickes Group. Wickes Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dr. Martens £764.90M 0.87 £68.97M £2.40 29.11 Wickes Group £1.64B 0.24 £29.25M £16.40 10.80

Is DOCS or WIX more profitable?

Dr. Martens has a net margin of 3.11% compared to Wickes Group's net margin of 2.35%. Wickes Group's return on equity of 29.52% beat Dr. Martens' return on equity. Company Net Margins Return on Equity Return on Assets Dr. Martens 3.11% 6.89% 8.12% Wickes Group 2.35% 29.52% 3.77%

Does the media refer more to DOCS or WIX?

In the previous week, Wickes Group had 1 more articles in the media than Dr. Martens. MarketBeat recorded 2 mentions for Wickes Group and 1 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 1.38 beat Wickes Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Martens 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Wickes Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dr. Martens (DOCS) Competitors

GBX 69.85 -0.25 (-0.35%)

As of 12:02 PM Eastern

Compare

DOCS vs. RMG, SPT, VTY, GEN, and WIX

Should you buy Dr. Martens stock or one of its competitors? MarketBeat compares Dr. Martens with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dr. Martens include Royal Mail (RMG), Spirent Communications (SPT), Vistry Group (VTY), Genuit Group (GEN), and Wickes Group (WIX). These companies are all part of the "computer software" industry.

How does Dr. Martens compare to Royal Mail?

Dr. Martens (LON:DOCS) and Royal Mail (LON:RMG) are both small-cap computer software companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

45.1% of Dr. Martens shares are held by institutional investors. 2.8% of Dr. Martens shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dr. Martens has a net margin of 3.11% compared to Royal Mail's net margin of 0.00%. Dr. Martens' return on equity of 6.89% beat Royal Mail's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Royal Mail	N/A	N/A	N/A

Dr. Martens has higher earnings, but lower revenue than Royal Mail. Royal Mail is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.87	£68.97M	£2.40	29.11
Royal Mail	£12.71B	0.00	N/A	£0.61	N/A

In the previous week, Dr. Martens had 1 more articles in the media than Royal Mail. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Royal Mail. Dr. Martens' average media sentiment score of 1.38 beat Royal Mail's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media.

Company	Overall Sentiment
Dr. Martens	Positive
Royal Mail	Neutral

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 3.7%. Royal Mail pays an annual dividend of GBX 0.17 per share. Dr. Martens pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royal Mail pays out 27.4% of its earnings in the form of a dividend.

Dr. Martens currently has a consensus target price of GBX 105, indicating a potential upside of 50.32%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Royal Mail.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Royal Mail	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dr. Martens beats Royal Mail on 12 of the 15 factors compared between the two stocks.

How does Dr. Martens compare to Spirent Communications?

Spirent Communications (LON:SPT) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

57.4% of Spirent Communications shares are owned by institutional investors. Comparatively, 45.1% of Dr. Martens shares are owned by institutional investors. 22.0% of Spirent Communications shares are owned by insiders. Comparatively, 2.8% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dr. Martens has higher revenue and earnings than Spirent Communications. Dr. Martens is trading at a lower price-to-earnings ratio than Spirent Communications, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spirent Communications	£471M	2.49	£16.67M	£0.01	16,032.26
Dr. Martens	£764.90M	0.87	£68.97M	£2.40	29.11

Dr. Martens has a net margin of 3.11% compared to Spirent Communications' net margin of 1.53%. Dr. Martens' return on equity of 6.89% beat Spirent Communications' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spirent Communications	1.53%	1.82%	2.77%
Dr. Martens	3.11%	6.89%	8.12%

In the previous week, Dr. Martens had 1 more articles in the media than Spirent Communications. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Spirent Communications. Dr. Martens' average media sentiment score of 1.38 beat Spirent Communications' score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Overall Sentiment
Spirent Communications	Neutral
Dr. Martens	Positive

Spirent Communications currently has a consensus price target of GBX 199, indicating a potential upside of 0.10%. Dr. Martens has a consensus price target of GBX 105, indicating a potential upside of 50.32%. Given Dr. Martens' stronger consensus rating and higher probable upside, analysts clearly believe Dr. Martens is more favorable than Spirent Communications.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spirent Communications	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Spirent Communications has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.253, suggesting that its stock price is 75% less volatile than the broader market.

Summary

Dr. Martens beats Spirent Communications on 11 of the 16 factors compared between the two stocks.

How does Dr. Martens compare to Vistry Group?

Vistry Group (LON:VTY) and Dr. Martens (LON:DOCS) are both small-cap consumer cyclical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Vistry Group presently has a consensus price target of GBX 463.30, indicating a potential upside of 94.66%. Dr. Martens has a consensus price target of GBX 105, indicating a potential upside of 50.32%. Given Vistry Group's higher probable upside, equities analysts plainly believe Vistry Group is more favorable than Dr. Martens.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vistry Group	4 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.80
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Vistry Group has a beta of 1.847, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.253, indicating that its stock price is 75% less volatile than the broader market.

Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vistry Group	£3.61B	0.21	£245.05M	£42.00	5.67
Dr. Martens	£764.90M	0.87	£68.97M	£2.40	29.11

Vistry Group has a net margin of 3.82% compared to Dr. Martens' net margin of 3.11%. Dr. Martens' return on equity of 6.89% beat Vistry Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vistry Group	3.82%	4.20%	3.43%
Dr. Martens	3.11%	6.89%	8.12%

68.4% of Vistry Group shares are owned by institutional investors. Comparatively, 45.1% of Dr. Martens shares are owned by institutional investors. 1.2% of Vistry Group shares are owned by insiders. Comparatively, 2.8% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vistry Group and Vistry Group both had 1 articles in the media. Dr. Martens' average media sentiment score of 1.38 beat Vistry Group's score of -0.28 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vistry Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Martens	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vistry Group and Dr. Martens tied by winning 7 of the 14 factors compared between the two stocks.

How does Dr. Martens compare to Genuit Group?

Genuit Group (LON:GEN) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Genuit Group pays an annual dividend of GBX 12.60 per share and has a dividend yield of 4.8%. Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 3.7%. Genuit Group pays out 70.8% of its earnings in the form of a dividend. Dr. Martens pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Genuit Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

74.4% of Genuit Group shares are owned by institutional investors. Comparatively, 45.1% of Dr. Martens shares are owned by institutional investors. 4.2% of Genuit Group shares are owned by company insiders. Comparatively, 2.8% of Dr. Martens shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Dr. Martens had 1 more articles in the media than Genuit Group. MarketBeat recorded 1 mentions for Dr. Martens and 0 mentions for Genuit Group. Dr. Martens' average media sentiment score of 1.38 beat Genuit Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Overall Sentiment
Genuit Group	Neutral
Dr. Martens	Positive

Dr. Martens has higher revenue and earnings than Genuit Group. Genuit Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genuit Group	£602.10M	1.10	£23.57M	£17.80	14.79
Dr. Martens	£764.90M	0.87	£68.97M	£2.40	29.11

Genuit Group presently has a consensus target price of GBX 430.40, indicating a potential upside of 63.53%. Dr. Martens has a consensus target price of GBX 105, indicating a potential upside of 50.32%. Given Genuit Group's stronger consensus rating and higher possible upside, research analysts clearly believe Genuit Group is more favorable than Dr. Martens.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genuit Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genuit Group has a beta of 1.469, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Dr. Martens has a beta of 0.253, suggesting that its stock price is 75% less volatile than the broader market.

Genuit Group has a net margin of 7.51% compared to Dr. Martens' net margin of 3.11%. Genuit Group's return on equity of 6.89% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genuit Group	7.51%	6.89%	4.59%
Dr. Martens	3.11%	6.89%	8.12%

Summary

Genuit Group beats Dr. Martens on 12 of the 18 factors compared between the two stocks.

How does Dr. Martens compare to Wickes Group?

Dr. Martens (LON:DOCS) and Wickes Group (LON:WIX) are both small-cap consumer cyclical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Dr. Martens pays an annual dividend of GBX 2.55 per share and has a dividend yield of 3.7%. Wickes Group pays an annual dividend of GBX 10.90 per share and has a dividend yield of 6.2%. Dr. Martens pays out 106.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Wickes Group pays out 66.5% of its earnings in the form of a dividend. Wickes Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Dr. Martens has a net margin of 3.11% compared to Wickes Group's net margin of 2.35%. Wickes Group's return on equity of 29.52% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	3.11%	6.89%	8.12%
Wickes Group	2.35%	29.52%	3.77%

45.1% of Dr. Martens shares are owned by institutional investors. Comparatively, 57.7% of Wickes Group shares are owned by institutional investors. 2.8% of Dr. Martens shares are owned by insiders. Comparatively, 0.7% of Wickes Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dr. Martens has a beta of 0.253, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Wickes Group has a beta of 0.857, suggesting that its share price is 14% less volatile than the broader market.

Dr. Martens has higher earnings, but lower revenue than Wickes Group. Wickes Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£764.90M	0.87	£68.97M	£2.40	29.11
Wickes Group	£1.64B	0.24	£29.25M	£16.40	10.80

In the previous week, Wickes Group had 1 more articles in the media than Dr. Martens. MarketBeat recorded 2 mentions for Wickes Group and 1 mentions for Dr. Martens. Dr. Martens' average media sentiment score of 1.38 beat Wickes Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Martens	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Wickes Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dr. Martens currently has a consensus target price of GBX 105, suggesting a potential upside of 50.32%. Wickes Group has a consensus target price of GBX 246.67, suggesting a potential upside of 39.20%. Given Dr. Martens' higher probable upside, equities research analysts plainly believe Dr. Martens is more favorable than Wickes Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Wickes Group	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Wickes Group beats Dr. Martens on 9 of the 17 factors compared between the two stocks.

Get Dr. Martens News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOCS vs. The Competition

Export

Metric	Dr. Martens	Footwear & Accessories Industry	Cyclical Sector	LON Exchange
Market Cap	£668.55M	£9.12B	£3.90B	£2.78B
Dividend Yield	3.64%	2.01%	3.50%	6.16%
P/E Ratio	29.11	19.54	78.33	365.72
Price / Sales	0.87	42.20	307.33	86,253.69
Price / Cash	14.29	20.28	30.81	27.85
Price / Book	1.85	4.08	3.33	7.92
Net Income	£68.97M	£168.67M	£249.12M	£5.89B
7 Day Performance	-3.65%	-1.49%	-0.79%	-0.87%
1 Month Performance	0.36%	0.68%	0.01%	-0.76%
1 Year Performance	-3.98%	14.13%	-0.02%	70.67%

Dr. Martens Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOCS Dr. Martens	4.1149 of 5 stars	GBX 69.85 -0.4%	GBX 105 +50.3%	-6.1%	£668.55M	£764.90M	29.11	890	Positive News
RMG Royal Mail	N/A	N/A	N/A	N/A	£1.98B	£12.71B	339.34	100
SPT Spirent Communications	0.2651 of 5 stars	GBX 198.80 flat	GBX 199 +0.1%	+4.0%	£1.17B	£471M	16,032.26	1,526
VTY Vistry Group	4.4908 of 5 stars	GBX 235.60 +2.1%	GBX 463.30 +96.6%	-60.7%	£748.24M	£3.61B	5.61	4,400
GEN Genuit Group	4.3346 of 5 stars	GBX 270.81 -0.1%	GBX 430.40 +58.9%	-29.3%	£682.40M	£602.10M	15.21	2,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:DOCS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dr. Martens (DOCS) Competitors

DOCS vs. RMG, SPT, VTY, GEN, and WIX

How does Dr. Martens compare to Royal Mail?

Summary

How does Dr. Martens compare to Spirent Communications?

Summary

How does Dr. Martens compare to Vistry Group?

Summary

How does Dr. Martens compare to Genuit Group?

Summary

How does Dr. Martens compare to Wickes Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dr. Martens (DOCS) Competitors

DOCS vs. RMG, SPT, VTY, GEN, and WIX

How does Dr. Martens compare to Royal Mail?

Do institutionals and insiders believe in DOCS or RMG?

Is DOCS or RMG more profitable?

Which has better earnings and valuation, DOCS or RMG?

Does the media favor DOCS or RMG?

Is DOCS or RMG a better dividend stock?

Do analysts rate DOCS or RMG?

Summary

How does Dr. Martens compare to Spirent Communications?

Do institutionals and insiders believe in SPT or DOCS?

Which has better earnings & valuation, SPT or DOCS?

Is SPT or DOCS more profitable?

Does the media prefer SPT or DOCS?

Do analysts prefer SPT or DOCS?

Which has more volatility and risk, SPT or DOCS?

Summary

How does Dr. Martens compare to Vistry Group?

Do analysts recommend VTY or DOCS?

Which has more volatility and risk, VTY or DOCS?

Which has stronger earnings and valuation, VTY or DOCS?

Is VTY or DOCS more profitable?

Do insiders & institutionals believe in VTY or DOCS?

Does the media favor VTY or DOCS?

Summary

How does Dr. Martens compare to Genuit Group?

Is GEN or DOCS a better dividend stock?

Do institutionals and insiders hold more shares of GEN or DOCS?

Does the media prefer GEN or DOCS?

Which has higher earnings & valuation, GEN or DOCS?

Do analysts prefer GEN or DOCS?

Which has more risk & volatility, GEN or DOCS?

Is GEN or DOCS more profitable?

Summary

How does Dr. Martens compare to Wickes Group?

Is DOCS or WIX a better dividend stock?

Is DOCS or WIX more profitable?

Do insiders and institutionals hold more shares of DOCS or WIX?

Which has more risk and volatility, DOCS or WIX?

Which has higher valuation and earnings, DOCS or WIX?

Does the media refer more to DOCS or WIX?

Do analysts prefer DOCS or WIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DOCS vs. The Competition

Dr. Martens Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools